Neovacs SA (FR:ALNEV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neovacs SA, a French biotech firm specializing in inflammatory and autoimmune therapies, has disclosed its share capital composition, revealing a total of 347,174,292 shares and equal voting rights as of August 31, 2024. The company has undergone a share consolidation and issues monthly reports on new share creation, including conversions of OCEANE bonds and exercises of BSA E, with detailed updates available on its website. However, the company warns of potential share price volatility and investor dilution due to the rapid sale of shares by the European High Growth Opportunities Securitization Fund and a trust responsible for the equitization of ORA financing.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.